Florida Cancer Specialists & Research Institute | Association Partnerships
About Florida Cancer Specialists & Research Institute, LLC: (Homepage)
Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with FCS participation.* Recognized for our research, FCS is a recipient of the national Clinical Trials Participation Award presented by the American Society of Clinical Oncology (ASCO). FCS physicians, trained in prestigious medical schools and research institutes, are consistently ranked nationally as Top Doctors by U.S. News & World Report.
Celebrating its 40th year in 2024, FCS has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies genomic-based treatment and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.
Latest from Florida Cancer Specialists & Research Institute
Addressing the State of Community Oncology in Florida and the Role of FLASCO
June 11th 2019Eric Harris, DO, hematologist/oncologist, Florida Cancer Specialists & Research Institute, gives Targeted Oncology an insiders perspective on the current state of community oncology in Florida and some ways the Florida Society of Clinical Oncology (FLASCO) aids in improving patient care by helping physicians.
Watch
Despite Initial Challenges, Oncology Practices See Benefit Moving to Oncology Care Model
May 14th 2019Oncology practices that adopt the OCM developed by the CMS face a tough road. The transformation requires changes in infrastructure encompassing administrative and care management service lines, as well as a change in philosophical outlook for clinicians and physician leadership; translational services for clinical interpretation; and internal reporting that is both costly and complex.
Read More
Patient Misconceptions About Clinical Trials Are a Common Source of Resistance, Expert Panel Says
April 8th 2019Before a community oncology practice considers getting involved in clinical trials research, there are many factorsto consider. Perhaps foremost is the fact that cancer clinical trials provide the evidence base for new advances in oncology.
Read More
Taking on the Hospital/Community Practice Cost Differential
January 24th 2018Just as CMS moves ahead with payment reforms designed to reduce the total cost of hospital care, results from a new study show that cancer treatment costs remain significantly lower at community oncology clinics compared with hospitals.
Read More
FDA Grants Approval to Co-Packaging of Ribociclib With Letrozole for Metastatic Breast Cancer
May 10th 2017The FDA has given its approval to co-packaging of the oral medications ribociclib (Kisqali) and letrozole (Femara) for the treatment of postmenopausal women with HR-positive, HER2-negative advanced breast cancer.
Read More
Ribociclib Results Promising for Elderly Patients With HR+/HER2- Breast Cancer
March 10th 2017The addition of the CDK4/6 inhibitor ribociclib to frontline letrozole reduced the risk of disease progression or death by 40% in elderly patients with hormone receptor-positive, HER2-negative advanced breast cancer.
Read More
